Follow Revolution Medicines to never miss an important update.
Loop Capital Markets set a price target of $318, which is significantly higher than where the stock currently trades. This move reflects growing confidence in the company's transition from a research firm into a commercial business that sells its own treatments. While this is a high target, the average across all analysts who follow the stock is about $252. The company is currently focused on getting its lead drug for pancreatic cancer through final testing and onto the market.
Source: Loop Capital Markets
Morgan Stanley set a target price of $255 for the company, which is higher than the average analyst target of $247. This suggests the firm sees more room for the stock to rise as the company moves closer to launching its first cancer drugs. While price targets are just estimates of where a stock might trade in a year, this move reflects growing confidence in the company's transition from a research firm into a commercial business.
Source: Morgan Stanley
The New England Journal of Medicine published data from a Phase 1/2 trial testing daraxonrasib in patients with non-small cell lung cancer. This drug, which the company calls RASONQUE, targets a specific family of cancer-causing proteins that have historically been very difficult to block without harming healthy tissue.
While the FDA recently approved this drug for pancreatic cancer, showing it works in lung cancer is the next big step for the company. Publication in a top-tier journal adds scientific weight to the results and suggests the drug could eventually treat a much wider group of patients. If the company can prove the same survival benefits in lung cancer that it saw in pancreatic trials, it would significantly expand its potential market.
Source: GlobeNewsWire
On August 27, the company signed agreements to lease four buildings in Redwood City, California. The leases start in late 2027 and 2028 and run through 2042. Once all four buildings are in use, the base rent will start at about 2.7 million dollars per month and rise by about 3 percent each year.
This is a major expansion of the company's physical footprint as it moves from a research firm toward becoming a commercial drug company. The timing aligns with the recent FDA approval of its first drug, as the company will need more space to house the teams required to sell and distribute its new treatment. Notably, the landlord is majority-owned by Farallon Capital, an investment firm that also owns about 6 percent of the company's stock.
Source: 8-K filing
Evercore ISI raised its target for the stock from $230 to $320. This move follows the recent approval of daraxonrasib, a drug designed to treat pancreatic cancer by targeting specific mutations that drive tumor growth. The new target is well above the current average analyst target of $248.
This change reflects growing confidence in the company's ability to turn its research into a commercial success. While the company is not yet profitable, the approval of its lead drug is a major step toward generating its first real revenue from a large and underserved patient population.
Source: Evercore ISI
Management consistently spends more on research than analysts expect, leading to a long streak of wider losses. This shows a team that prioritizes clinical speed over meeting quarterly profit targets.
| Expectation | |
|---|---|
| EPS | $-2.40 |
| Revenue | $24M |
Follow Revolution Medicines to get the latest and most important updates.
Follow RVMD